tailieunhanh - báo cáo khoa học: " Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis | Zhou et al. Journal of Experimental Clinical Cancer Research 2011 30 72 http content 30 1 72 Journal of Experimental Clinical Cancer Research RESEARCH Open Access Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment a meta-analysis Wen-Bin Zhou1 Peng-Ling Zhang2 Xiao-An Liu1 Tao Yang3 and Wei He3 Abstract Background Zoledronic acid ZOL is widely used for preventing bone loss in early breast cancer patients. However the adverse effects caused by ZOL itself should not be neglected. Musculoskeletal disorders were common after ZOL administration and distressing to the patients. Up to now no precise estimation of musculoskeletal disorders has been made. Methods Relevant randomized clinical trials were selected by searching the electronic database PubMed and a meta-analysis was conducted. Results Four trials reported musculoskeletal disorders of ZOL treatment versus no ZOL including 2684 patients treated with ZOL and 2712 patients without ZOL treatment. Compared to patients without ZOL treatment patients treated with ZOL had a significantly higher risk of arthralgia risk ratio RR 95 confidence interval CI P for heterogeneity and bone pain RR 95 CI P for heterogeneity . Three clinical trials reported the complications of upfront versus delayed ZOL treatment including 1091 patients with upfront ZOL and 1110 patients with delayed ZOL. The rate of bone pain in upfront group 119 824 was significantly higher than that in delayed group 74 836 RR 95 CI P for heterogeneity . Conclusions Our meta-analysis suggested that treatment with ZOL was significantly associated to the occurrence of arthralgia and bone pain. Moreover higher rate of bone pain was observed in patients treated with upfront ZOL compared with delayed ZOL treatment. More attentions should be paid to patients treated with ZOL especially for immediate ZOL. For patients with low risk of